Phase II study of S-1 on alternate days plus bevacizumab in patients aged ≥ 75 years with metastatic colorectal cancer (J-SAVER)

Toshikazu Moriwaki,Yoshinori Sakai,Hiroyasu Ishida,Yoshiyuki Yamamoto,Shinji Endo,Hideaki Kuramochi,Mikio Sato,Yukimasa Hatachi,Yoshiaki Bando,Takashi Maeba,Kazuto Ikezawa,Mitsuo Shimada,Kenji Amagai,Masamitsu Morimoto,Kazuma Kobayashi,Akihito Tsuji,Tomohiro Nishina,Ichinosuke Hyodo

Phase II study of S-1 on alternate days plus bevacizumab in patients aged ≥ 75 years with metastatic colorectal cancer (J-SAVER)

2019

Toshikazu Moriwaki
Yoshinori Sakai
Hiroyasu Ishida
Yoshiyuki Yamamoto
Shinji Endo
Hideaki Kuramochi
Mikio Sato
Yukimasa Hatachi
Yoshiaki Bando
Takashi Maeba
Kazuto Ikezawa
Mitsuo Shimada
Kenji Amagai
Masamitsu Morimoto
Kazuma Kobayashi
Akihito Tsuji
Tomohiro Nishina
Ichinosuke Hyodo

Background Alternate-day administration of S-1 is thought to reduce toxicities. This phase II study evaluated S-1 on alternate days combined with bevacizumab as first-line treatment for elderly patients with metastatic colorectal cancer.

Keywords:

Bevacizumab
General surgery
Phases of clinical research
Colorectal cancer
Oncology
Medicine
Internal medicine
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations